The CEO's ~$18.9M sale is the dominant signal — it is large, concentrated, and not offset by any insider buying. While the sales follow option exercises (tax-driven), the sheer size and timing suggest potential caution. Monitor for any upcoming clinical data readouts, earnings, or financing events that could explain the selling. The 95% bullish analyst consensus creates a potential asymmetry if negative news emerges.
Price Chart
Executive Summary
CEO Marino Garcia and General Counsel Adam Veness executed a cluster of open-market sales totaling ~$20.0M over two days (Aug 7-10, 2026), following option exercises at much lower strike prices. The CEO alone sold ~$18.9M at ~$108-111/share, while the GC sold ~$2.2M. These are large, concentrated sales by top executives at a $6.3B biotech with a 95% bullish analyst consensus, creating a notable bearish signal that warrants close monitoring.
Key Financial Metrics
Key Facts
- CEO Marino Garcia sold 166,000 shares in open-market transactions on Aug 7, 2026, totaling ~$18.9M at prices between $107.49 and $110.76.
- General Counsel Veness sold 20,000 shares on Aug 7 and 10, 2026, totaling ~$2.2M at prices between $110.38 and $111.18.
- All sales followed option exercises: CEO exercised 292,000 options at $0-$8.44 strike; GC exercised 23,833 options at $0-$17.88 strike.
- Total open-market sales by the two insiders in the cluster: ~$20.0M, representing approximately 0.32% of DNTH's $6.3B market cap.
- The cluster occurred within a 7-day window (Aug 7-10), with no open-market purchases by any insider.
- DNTH has a 95% bullish analyst consensus (21 Buy, 1 Hold) and $6.3B market cap.
Financial Impact
Insider sales of ~$20.0M represent 0.32% of market cap — modest in proportionality but significant in absolute dollar terms and executive seniority.
Risk Factors
- CEO selling ~$18.9M in a concentrated window could signal management's view that the stock is fully valued or that near-term catalysts are uncertain.
- No insider buying to offset the selling — the cluster is entirely one-directional (sell).
- Biotech stocks are binary event-driven — large insider sales ahead of data readouts can be a red flag.
- The stock has rallied significantly (options exercised at $8.44 vs. sale price ~$108), creating a natural profit-taking incentive.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-DNTH-1786482561581 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▲ +8.12% | ▲ +6.22% | $89.96 (+19.97%) |
Aug 10, 2026 7w ago | 144 | $108.49 $107.04 | ▼ −1.34% | ▼ −0.28% | $89.96 (−17.08%) |
Jun 29, 2026 13w ago | Press Release | $95.68 $103.87 | ▲ +8.56% | ▲ +8.84% | $89.96 (−5.98%) |
Jun 12, 2026 16w ago | 8-K | $82.07 $97.60 | ▲ +18.92% | ▲ +17.14% | $89.96 (+9.61%) |
Jun 11, 2026 16w ago | Institutional Cluster | $76.45 $100.03 | ▲ +30.84% | ▲ +28.95% | $89.96 (+17.67%) |
May 5, 2026 21w ago | 8-K | $90.42 $84.97 | ▼ −6.03% | ▼ −8.81% | $89.96 (−0.51%) |
Mar 12, 2026 29w ago | Press Release | $77.86 $90.00 | ▲ +15.59% | ▲ +12.00% | $89.96 (+15.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access